A Pill to Hold What the Injection Lost

Plenty of people would like to lose the weight on an injection and then hold it with something simpler. A phase 3b trial tested exactly that handover: participants who had lost weight on injectable therapy moved to daily oral orforglipron or to placebo. The pill maintained 79.3% of the reduction against 37.6% on placebo at 52 weeks.^[1]

The result

The estimated treatment difference was 41.7 percentage points, with a confidence interval from 24.4 to 59.0 — a wide interval, but comfortably clear of zero. All key secondary endpoints were met. The commonest adverse events were gastrointestinal and mostly mild to moderate.^[1]

The placebo figure is worth its own moment: people who switched to nothing still held 37.6% of what they had lost, at a year. That is a third data point against the popular account that stopping means regaining everything — consistent with the real-world discontinuation data and with SURMOUNT-4’s placebo arm.

The comparison that was not run

There was no arm that stayed on the injection.

The authors name this limitation themselves.^[1] It matters more than any figure in the trial, because it is the question people actually have. Nobody wonders whether a pill beats stopping — obviously it does. What they want to know is whether switching costs them anything against staying on what was working.

We have one adjacent answer. In SURMOUNT-MAINTAIN, people who stepped down to a lower injectable dose held less than those who stayed at full dose, and needed rescue therapy three times as often — 25% against 8%, covered in the maintenance trial. Less drug held much of the loss and measurably less of it. Whether a switch to an oral agent behaves the same way is untested.

Why an oral maintenance option matters commercially

The authors describe orforglipron as a potentially globally scalable option, and that word is doing real work. Orforglipron is a small molecule rather than a peptide, so it can be manufactured at a scale injectable peptides cannot — the constraint behind the shortages this register has tracked from the commercial end.

A world where the expensive, supply-constrained injectable does the losing and a manufacturable pill does the holding is a plausible answer to a real bottleneck. It is also a commercially convenient story, and worth watching for whether the maintenance data ever gets a fair comparison against simply continuing.